AIMS/HYPOTHESIS: Glucokinase (GCK) acts as a glucose sensor in the pancreatic beta cell and regulates insulin secretion. In the gene encoding GCK the heterozygous mutations that result in enzyme inactivation cause MODY2. Functional studies of naturally occurring GCK mutations associated with hyperglycaemia provide further insight into the biochemical basis of glucose sensor regulation. MATERIALS AND METHODS: Identification of GCK mutations in selected MODY patients was performed by single-strand conformation polymorphism and direct sequencing. The kinetic parameters and thermal stability of recombinant mutant human GCK were determined, and in pull-down assays the effect of these mutations on the association of GCK with glucokinase (hexokinase 4) regulator (GCKR, also known as glucokinase regulatory protein [GKRP]) and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1, also known as PFK2) was tested. RESULTS: We identified three novel GCK mutations: the insertion of an asparagine residue at position 161 (inserN161) and two missense mutations (M235V and R308W). We also identified a fourth mutation (R397L) reported in a previous work. Functional characterisation of these mutations revealed that insertion of asparagine residue N161 fully inactivates GCK, whereas the M235V and R308W mutations only partially impair enzymatic activity. In contrast, GCK kinetics was almost unaffected by the R397L mutation. Although none of these mutations affected the interaction of GCK with PFKFB1, we found that the R308W mutation caused protein instability and increased the strength of interaction with GCKR. CONCLUSIONS/ INTERPRETATION: Our results show that different MODY2 mutations impair GCK function through different mechanisms such as enzymatic activity, protein stability and increased interaction with GCKR, helping further elucidate the regulation of GCK activity.
AIMS/HYPOTHESIS: Glucokinase (GCK) acts as a glucose sensor in the pancreatic beta cell and regulates insulin secretion. In the gene encoding GCK the heterozygous mutations that result in enzyme inactivation cause MODY2. Functional studies of naturally occurring GCK mutations associated with hyperglycaemia provide further insight into the biochemical basis of glucose sensor regulation. MATERIALS AND METHODS: Identification of GCK mutations in selected MODY patients was performed by single-strand conformation polymorphism and direct sequencing. The kinetic parameters and thermal stability of recombinant mutant humanGCK were determined, and in pull-down assays the effect of these mutations on the association of GCK with glucokinase (hexokinase 4) regulator (GCKR, also known as glucokinase regulatory protein [GKRP]) and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1, also known as PFK2) was tested. RESULTS: We identified three novel GCK mutations: the insertion of an asparagine residue at position 161 (inserN161) and two missense mutations (M235V and R308W). We also identified a fourth mutation (R397L) reported in a previous work. Functional characterisation of these mutations revealed that insertion of asparagine residue N161 fully inactivates GCK, whereas the M235V and R308W mutations only partially impair enzymatic activity. In contrast, GCK kinetics was almost unaffected by the R397L mutation. Although none of these mutations affected the interaction of GCK with PFKFB1, we found that the R308W mutation caused protein instability and increased the strength of interaction with GCKR. CONCLUSIONS/ INTERPRETATION: Our results show that different MODY2 mutations impair GCK function through different mechanisms such as enzymatic activity, protein stability and increased interaction with GCKR, helping further elucidate the regulation of GCK activity.
Authors: J X Perez; T Roig; A Manzano; M Dalmau; J Boada; F Ventura; J L Rosa; J Bermudez; R Bartrons Journal: Am J Physiol Cell Physiol Date: 2000-11 Impact factor: 4.249
Authors: E A Davis; A Cuesta-Muñoz; M Raoul; C Buettger; I Sweet; M Moates; M A Magnuson; F M Matschinsky Journal: Diabetologia Date: 1999-10 Impact factor: 10.122
Authors: Anna L Gloyn; Stella Odili; Dorothy Zelent; Carol Buettger; Harriet A J Castleden; Anna M Steele; Amanda Stride; Chyio Shiota; Mark A Magnuson; Renata Lorini; Giuseppe d'Annunzio; Charles A Stanley; Jae Kwagh; Emile van Schaftingen; Maria Veiga-da-Cunha; Fabrizio Barbetti; Pete Dunten; Yi Han; Joseph Grimsby; Rebecca Taub; Sian Ellard; Andrew T Hattersley; Franz M Matschinsky Journal: J Biol Chem Date: 2005-01-25 Impact factor: 5.157
Authors: Tiffany Fleet; Bin Zhang; Fumin Lin; Bokai Zhu; Subhamoy Dasgupta; Erin Stashi; Bryan Tackett; Sundararajah Thevananther; Kimal I Rajapakshe; Naomi Gonzales; Adam Dean; Jianqiang Mao; Nikolai Timchenko; Anna Malovannaya; Jun Qin; Cristian Coarfa; Francesco DeMayo; Clifford C Dacso; Charles E Foulds; Bert W O'Malley; Brian York Journal: Proc Natl Acad Sci U S A Date: 2015-10-20 Impact factor: 11.205
Authors: Nicholas J Ollberding; Iona Cheng; Lynne R Wilkens; Brian E Henderson; Michael N Pollak; Laurence N Kolonel; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-02-21 Impact factor: 4.254
Authors: Paul M Ridker; Guillaume Pare; Alex Parker; Robert Y L Zee; Jacqueline S Danik; Julie E Buring; David Kwiatkowski; Nancy R Cook; Joseph P Miletich; Daniel I Chasman Journal: Am J Hum Genet Date: 2008-04-24 Impact factor: 11.025
Authors: JaeAnn M Dwulet; Nurin W F Ludin; Robert A Piscopio; Wolfgang E Schleicher; Ong Moua; Matthew J Westacott; Richard K P Benninger Journal: Biophys J Date: 2019-11-05 Impact factor: 4.033
Authors: Claire L Dubois; Hung Ping Shih; Philip A Seymour; Nisha A Patel; James M Behrmann; Victoria Ngo; Maike Sander Journal: PLoS One Date: 2011-08-02 Impact factor: 3.240